Document:

Amended and Restated Investors' Rights Agreement

 EXHIBIT 4.2 
 EMPHASYS MEDICAL, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 This Fourth Amended and Restated Investors’ Rights Agreement (the “Agreement”) is made as of the 29th day of June
2006, by and among Emphasys Medical, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock
listed on Exhibit A attached hereto (the “Prior Investors”), and the holders of the Company’s Series E Preferred Stock also listed on Exhibit A attached hereto (the “Series E Investors,”
and, together with the Prior Investors, the “Investors”). 
 RECITALS 
 A. On July 16, 2001, the Company and certain of the Prior Investors entered into an Amended and Restated Investors’ Rights Agreement, as
amended on March 26, 2002 (the “Investors’ Rights Agreement”), as further amended and restated by a Second Amended and Restated Investors’ Rights Agreement made as of January 31, 2003, and as further amended and
restated by a Third Amended and Restated Investors’ Rights Agreement made as of June 17, 2004, pursuant to which the holders of Series D Preferred Stock became parties to the Investors’ Rights Agreement (the “Prior Rights
Agreement”), pursuant to which the Company granted the Prior Investors certain rights. 
 B. The Company and the Series E Investors
have entered into a Series E Preferred Stock Purchase Agreement (the “Purchase Agreement”) of even date herewith pursuant to which the Company desires to sell to the Series E Investors and the Series E Investors desire to purchase
from the Company shares of the Company’s Series E Preferred Stock. A condition to the Series E Investors’ obligations under the Purchase Agreement is that the Company and the Investors enter into this Agreement in order to amend and
restate the Prior Rights Agreement to include the Series E Investors and provide the Investors with, among other things, (i) certain rights to register shares of the Company’s Common Stock issuable upon conversion of the Series A
Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock held by the Investors, (ii) certain rights to receive or inspect information pertaining to the Company, and (iii) a
right of first offer with respect to certain issuances by the Company of its securities. 
 C. The Company and the Prior Investors desire to
so amend and restate the Prior Rights Agreement. Effective and contingent upon execution of this Agreement by the Company, and the holders of a majority of the Registrable Securities then outstanding, the Prior Rights Agreement, as amended,
is hereby declared null and void and is amended and restated in its entirety to read as set forth in this Agreement, and the Company and the Investors hereby agree to be bound by the provisions hereof as their sole agreement of the Company and the
Investors with respect to registration rights of the Company’s securities and certain other rights as set forth herein. 

 AGREEMENT 
 The parties hereby agree as follows: 
 1. Registration Rights. The Company and the Investors
covenant and agree as follows: 
 1.1 Definitions. For purposes of this Section 1: 
 (a) The terms “register,” “registered,” and “registration” refer to a registration effected by
preparing and filing a registration statement or similar document in compliance with the Securities Act of 1933, as amended (the “Securities Act”), and the declaration or ordering of effectiveness of such registration statement or
document; 
 (b) The term “Registrable Securities” means (i) the shares of Common Stock issuable or issued upon
conversion of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock other than shares for which registration rights have terminated pursuant to Section 1.15
hereof, and (ii) any other shares of Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange
for or in replacement of, the shares listed in (i); provided, however, that the foregoing definition shall exclude in all cases any Registrable Securities sold by a person in a transaction in which his or her rights under this
Agreement are not assigned. Notwithstanding the foregoing, Common Stock or other securities shall only be treated as Registrable Securities if and so long as they have not been (A) sold to or through a broker or dealer or underwriter in a
public distribution or a public securities transaction, (B) sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof, in each case so that all transfer
restrictions, and restrictive legends with respect thereto, if any, are removed upon the consummation of such sale, or (C) the Holder thereof is entitled to exercise any right provided in Section 1 in accordance with Section 1.15
hereof; 
 (c) The number of shares of “Registrable Securities then outstanding” shall be the number of shares of Common
Stock outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities which are, Registrable Securities; 
 (d) The term “Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.12 of this Agreement; 
 (e) The term “Form S-3” means such form under the Securities Act as in effect on the date hereof or any successor form under the
Securities Act that permits significant incorporation by reference of the Company’s subsequent public filings under the Securities Exchange Act of 1934; 
  

 -2- 

 (f) The term “SEC” means the Securities and Exchange Commission; and 
 (g) The term “Qualified IPO” means a firm commitment underwritten public offering by the Company of shares of its Common Stock pursuant
to a registration statement under the Securities Act, the public offering price of which is not less than $7.20 per share (appropriately adjusted for any stock split, dividend combination or other recapitalization) and which results in aggregate
cash proceeds to the Company of $30,000,000 (net of underwriting discounts and commissions). 
 1.2 Request for Registration.

 (a) If the Company shall receive at any time after the earlier of (i) June 29, 2009, or (ii) six (6) months after the
effective date of the first registration statement for a public offering of securities of the Company (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to a stock option, stock
purchase or similar plan or an SEC Rule 145 transaction), a written request from (u) the Holders of a majority of the Registrable Securities then outstanding consisting of Common Stock issued or issuable upon the conversion of Series A
Preferred Stock, (v) the Holders of a majority of Registrable Securities then outstanding consisting of Common Stock issued or issuable upon the conversion of Series B Preferred Stock, (w) the Holders of at least 20% of Registrable
Securities then outstanding consisting of Common Stock issued or issuable upon the conversion of Series C Preferred Stock covering the registration of not less than 20% of the Registrable Securities then outstanding consisting of Common Stock issued
or issuable upon the conversion of Series C Preferred Stock, (x) the Holders of at least 20% of Registrable Securities then outstanding consisting of Common Stock issued or issuable upon the conversion of Series D Preferred Stock covering the
registration of not less than 20% of the Registrable Securities then outstanding consisting of Common Stock issued or issuable upon the conversion of Series D Preferred Stock, (y) the Holders of at least 20% of Registrable Securities then
outstanding consisting of Common Stock issued or issuable upon the conversion of Series E Preferred Stock covering the registration of not less than 20% of the Registrable Securities then outstanding consisting of Common Stock issued or issuable
upon the conversion of Series E Preferred Stock, or (z) the Holders of a majority of all Registrable Securities then outstanding, that the Company file a registration statement under the Securities Act covering the registration of not less than
an aggregate offering price of $5,000,000, net of underwriting discounts and commissions, then the Company shall, within ten (10) days of the receipt thereof, give written notice of such request to all Holders and shall, subject to the
limitations of subsection 1.2(b), use its best efforts to effect as soon as practicable, and in any event within 90 days of the receipt of such request, the registration under the Securities Act on Form S-1 (or any other form which
includes substantially the same information as would be required to be included in a registration statement or such form), unless a majority in interest of the Initiating Holders shall have agreed otherwise in writing, of all Registrable Securities
which the Holders request to be registered within twenty (20) days of the mailing of such notice by the Company in accordance with Section 3.4. 
  

 -3- 

 (b) If the Holders initiating the registration request hereunder (“Initiating Holders”)
intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.2 and the Company shall include such information
in the written notice referred to in subsection 1.2(a). The underwriter will be selected by a majority in interest of the Initiating Holders and shall be reasonably acceptable to the Company. In such event, the right of any Holder to include
his Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a
majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in subsection 1.5(e))
enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing
that marketing factors require a limitation of the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares
of Registrable Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned
by each Holder; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities (including without limitation securities to be sold by the
Company) are first entirely excluded from the underwriting. 
 (c) Notwithstanding the foregoing, if the Company shall furnish to Holders
requesting a registration statement pursuant to this Section 1.2, a certificate signed by the President of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the
Company and its stockholders for such registration statement to be filed and it is therefore essential to defer the filing of such registration statement for a specified period of not more than 90 days after receipt of the request of the Initiating
Holders, the Company shall have the right to defer such filing for such period; provided, however, that the Company may not utilize this right more than once in any twelve-month period. 
 (d) In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.2:

 (i) After the Company has effected two (2) registrations pursuant to this Section 1.2 and such registrations have been declared
or ordered effective; 
 (ii) During the one hundred eighty (180) day period commencing with the effective date of the first firmly
underwritten offering of the Company’s Common Stock; 
 (iii) If the Initiating Holders have received, within thirty (30) days of
their request, notice from the Company of the Company’s intent to file a registration 

  

 -4- 

 
statement subject to Section 1.3 hereof and provided that the Company is actively employing in good faith all reasonable efforts to include in such
registration all Registrable Securities requested to be so included in accordance with Section 1.3 and to cause such registration statement to become effective, for ninety (90) days following the Initiating Holders’ receipt of such
notice; or 
 (iv) If the Initiating Holders propose to dispose of shares of Registrable Securities (other than by means of an underwriting)
that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.4 below. 
 1.3 Company
Registration. If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities
Act in connection with the public offering of such securities (other than a registration relating solely to the sale of securities to participants in a Company stock plan or a transaction covered by Rule 145 under the Securities Act, or any
registration on any form which does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities), the Company shall, at such time, promptly give each
Holder written notice of such registration. Upon the written request of each Holder given within twenty (20) days after receipt of such notice from the Company in accordance with Section 3.5, the Company shall, subject to the provisions of
Section 1.8, cause to be included in such registration and in any underwriting involved therein all of the Registrable Securities that each such Holder has requested to be registered. 
 1.4 Form S-3 Registration. In case the Company shall receive from any Holder or Holders of Registrable Securities then outstanding a
written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will:

 (a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and

 (b) as soon as practicable, effect such registration and all such qualifications and compliances as may be so requested and as would
permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder
or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect
any such registration, qualification or compliance, pursuant to this Section 1.4: (i) if Form S-3 is not available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the
Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of less than $500,000;
(iii) if the Company shall furnish to the Holders a certificate signed by the President of the Company stating that in the good faith judgment of the Board of Directors of the 

  

 -5- 

 
Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 Registration to be effected for a specified period not
to exceed 90 days from the Company’s receipt of the request of the Holder or Holders under this Section 1.4, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for such specified
period; provided, however, that the Company shall not utilize this right more than once in any twelve month period; (iv) if the Company has, within the twelve (12) month period preceding the date of such request, already
effected two registrations on Form S-3 for the Holders pursuant to this Section 1.4; (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of
process in effecting such registration, qualification or compliance; or (vi) during the period ending ninety (90) days after the effective date of a registration statement subject to Section 1.3. 
 (c) Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to
be registered as soon as practicable after receipt of the request or requests of the Holders. Registrations effected pursuant to this Section 1.4 shall not be counted as demands for registration or registrations effected pursuant to
Sections 1.2 or 1.3, respectively. 
 1.5 Obligations of the Company. Whenever required under this Section 1 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file
with the SEC a registration statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for up to one hundred eighty (180) days. Such registration statement shall be for an offering to be made on a continuous or delayed basis (a so-called “shelf registration
statement”) if the Company is eligible for the use thereof and the Holders of a majority of the Registrable Securities to be registered have requested a shelf registration statement. 
 (b) At the written request of the Holders requesting registration of Registrable Securities pursuant to this Section 1, provide to one legal
counsel designated by such Holders as provided in Section 1.7 below, without charge and at least five (5) days prior to filing with the SEC, the registration statement and any amendment or supplement to the registration statement, for
review. The Company shall negotiate in good faith with such designated counsel toward resolving any reasonable objection of such designated counsel that the registration statement or any amendment or supplement to the registration statement or
prospectus does not comply in all material respects with the requirements of the Securities Act and the rules and regulations promulgated thereunder prior to filing the registration statement, supplement or amendment, unless in the opinion of
counsel to the Company filing of the amendment or supplement is reasonably necessary to protect the Company from liability under applicable federal or state law and the filing will not violate applicable law. In addition, the Company shall provide
to the designated counsel copies of any correspondence with the SEC or its staff relating to the filing or effectiveness of the registration statement. The Company shall not be required to 

  

 -6- 

 
provide copies of reports filed under the Exchange Act to such designated counsel for review and shall not suffer any adverse consequence for failure to
comply with this Agreement if the failure to comply is caused by a delay in review or comment by such designated counsel. 
 (c) Comply in
all material respects with the provisions of the Securities Act regarding disposition of the Registrable Securities covered by the registration statement and comply in all material respects with all applicable rules and regulations of the SEC in
connection with any registration under this Agreement. 
 (d) Prepare and file with the SEC such amendments and supplements to such
registration statement and the prospectus used in connection with such registration statement as may be necessary to keep such registration statement effective and comply with the provisions of the Securities Act with respect to the disposition of
all securities covered by such registration statement for up to one hundred eighty (180) days. 
 (e) Furnish to the Holders such
numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable
Securities owned by them. 
 (f) Use its best efforts to register and qualify the securities covered by such registration statement under
such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or jurisdictions. 
 (g) Promptly notify the Holders upon receipt of notice
by the Company of the time when the registration statement has become effective or a supplement to any prospectus forming a part of the registration statement has been filed. 
 (h) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary
form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. Use its best efforts to cooperate in the underwritten offering, including
causing key executives of the Company to participate under the direction of the managing underwriter in “road show” presentations in such locations and of such duration as in the reasonable judgement of such managing underwriter are
appropriate. 
 (i) Immediately notify each Holder of Registrable Securities covered by such registration statement at any time when a
prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material
fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing, such obligation to continue for such time as the registration statement
remains effective. 
  

 -7- 

 (j) Cause all such Registrable Securities registered hereunder to be listed on each securities exchange
on which similar securities issued by the Company are then listed. 
 (k) Provide a transfer agent and registrar for all Registrable
Securities registered hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 
 (l) Use its best efforts to furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the
underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through underwriters, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such
registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters and to the Holders requesting registration of Registrable Securities and (ii) a letter dated such
date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if
any, and to the Holders requesting registration of Registrable Securities. 
 (m) Notify the Holders promptly after the Company receives
(i) notice that the SEC has issued a stop order suspending the effectiveness of a registration statement or initiated or threatened to initiate any proceeding for that purpose, or (ii) any notice with respect to the suspension or
threatened suspension of the registration or qualification of any Registrable Securities under the securities or Blue Sky laws of any jurisdiction. In addition, the Company shall promptly use its best efforts to prevent the issuance of any stop
order or suspension of registration or qualification, or to obtain the withdrawal of any stop order or suspension of registration or qualification if issued. 
 1.6 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling
Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be required to effect the registration of such
Holder’s Registrable Securities. The Company shall have no obligation with respect to any registration requested pursuant to Section 1.2 or Section 1.4 of this Agreement if, as a result of the application of the preceding sentence,
the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price required to originally
trigger the Company’s obligation to initiate such registration as specified in subsection 1.2(a) or subsection 1.4(b)(2), whichever is applicable. 
 1.7 Expenses of Registration. 
 (a) Demand Registration. All expenses other than
underwriting discounts and commissions incurred in connection with registrations, filings or qualifications 

  

 -8- 

 
pursuant to Section 1.2, including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, fees and
disbursements of counsel for the Company, and the reasonable fees and disbursements of one counsel for the selling Holders selected by them, shall be borne by the Company; provided, however, that the Company shall not be required to
pay for any expenses of any registration proceeding begun pursuant to Section 1.2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case
all participating Holders shall bear such expenses), unless (i) the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 1.2 or (ii) if at the time of such
withdrawal, the Holders have learned of a material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their request, in which case the Holders will not be required to pay any of such
expenses. 
 (b) Company Registration. All expenses other than underwriting discounts and commissions incurred in connection
with registrations, filings or qualifications of Registrable Securities pursuant to Section 1.3 for each Holder (which right may be assigned as provided in Section 1.12), including (without limitation) all registration, filing, and
qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holder or Holders selected by them shall be borne by the Company.

 (c) Registration on From S-3. All expenses other than underwriting discounts and commissions incurred in connection with
registrations, filings or qualifications of Registrable Securities pursuant to Section 1.4 for each Holder (which right may be assigned as provided in Section 1.12), including (without limitation) all registration, filing, and
qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holder or Holders selected by them shall be borne by the Company.

 1.8 Underwriting Requirements. In connection with any offering involving an underwriting of shares of the Company’s
capital stock, the Company shall not be required under Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters
selected by it (or by other persons entitled to select the underwriters), subject to compliance with the terms of Section 1.10 herein, and then only in such quantity as the underwriters determine reasonably in their sole discretion and so
advise the Company and the Holders in writing will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the
amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering pursuant to Section 1.3
only that number of such securities, including Registrable Securities, which the underwriters determine reasonably in their sole discretion will not jeopardize the success of the offering (the securities so included to be apportioned pro rata among
the selling stockholders participating under Section 1.3 according to the total amount of securities entitled to be included therein owned by each selling stockholder or 

  

 -9- 

 
in such other proportions as shall mutually be agreed to by such selling stockholders) but in no event shall the amount of securities of such selling Holders
included in the offering be reduced below twenty percent (20%) of the total amount of securities (including without limitation any securities to be sold by the Company) included in such offering, unless such offering is the initial public
offering of the Company’s securities, in which case, such selling stockholders may be excluded if the underwriters make the determination described above and no other stockholder’s securities are included pursuant to Section 1.3;
provided, however, that if any of the Holders’ securities are excluded from a registration pursuant to operation of this Section 1.8, then no party (other than a Holder) shall sell shares in such registration other than the
Company. For purposes of the preceding parenthetical concerning apportionment, for any selling stockholder which is a holder of Registrable Securities and which is a partnership or corporation, the partners, retired partners and stockholders of such
holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling stockholder,” and any pro-rata reduction with
respect to such “selling stockholder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “selling stockholder,” as defined in this sentence.

 1.9 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying
any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 
 1.10 Indemnification. In the event any Registrable Securities are included in a registration statement under this Section 1: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder (which for purposes of this Section 1.10(a) shall be
deemed to include the officers, directors, employees, agents, members and partners of a Holder), any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning
of the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the
Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a
“Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the
Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will pay to each such Holder, underwriter or
controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the 

  

 -10- 

 
indemnity agreement contained in this subsection 1.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or
action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable to any Holder, underwriter or controlling person for any such loss, claim, damage,
liability, or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly by any such Holder, underwriter or controlling person for use in
connection with such registration. 
 (b) To the extent permitted by law, each selling Holder will, severally and not jointly, indemnify and
hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter, any other Holder selling
securities in such registration statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the
Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent)
that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any legal or other expenses
reasonably incurred by any person intended to be indemnified pursuant to this subsection 1.10(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the
indemnity agreement contained in this subsection 1.10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall
not be unreasonably withheld; provided, that in no event shall any indemnity under this subsection 1.10(b) exceed the net proceeds (after deduction of all underwriters’ discounts and commissions and all other expenses paid by such
Holder in connection with the registration in question) from the offering received by such Holder, except in the case of willful fraud by such Holder. 
 (c) Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together
with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the reasonable fees and expenses to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure
to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, shall not relieve such indemnifying party of any liability to the indemnified party under this Section 1.10, 

  

 -11- 

 
except and solely to the extent that such indemnifying party is actually prejudiced by such failure to give notice. If, within a reasonable time after
receipt of the notice, such indemnifying party shall not have assumed the defense of the action, such indemnifying party shall be responsible for any legal or other expenses incurred by such indemnified party incurred in connection with the defense
of the action. 
 (d) If the indemnification provided for in this Section 1.10 is held by a court of competent jurisdiction to be
unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or
payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other
in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations; provided, that in no event shall any contribution by a Holder under this
Subsection 1.10(d) exceed the net proceeds (after deduction of all underwriters’ discounts and commissions and all other expenses paid by such Holder in connection with the registration in question) from the offering received by such Holder,
except in the case of willful fraud by such Holder. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such
statement or omission. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained
in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 (f) The obligations of the Company and Holders under this Section 1.10 shall survive the completion of any offering of Registrable Securities in a
registration statement under this Section 1, and otherwise. 
 1.11 Reports Under Securities Exchange Act of 1934. With a
view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to: 
 (a) make and keep public information available, as
those terms are understood and defined in SEC Rule 144, at all times after ninety (90) days after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public so long
as the Company remains subject to the periodic reporting requirements under Sections 13 or 15(d) of the Exchange Act; 
  

 -12- 

 (b) take such action, including the voluntary registration of its Common Stock under Section 12 of
the Exchange Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration statement
filed by the Company for the offering of its securities to the general public is declared effective; 
 (c) file with the SEC in a timely
manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and 
 (d) furnish to any
Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days
after the effective date of the first registration statement filed by the Company), the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose
securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such
other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 
 1.12 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Section 1
may be assigned (but only with all related obligations) by a Holder to (a) a transferee or assignee of at least 250,000 shares of such securities (as adjusted for stock splits, stock dividends and the like), (b) a transferee or assignee
who is a partner or retired partner of a Holder that is a partnership or a member or former member of a Holder that is a limited liability company, (c) a transferee or assignee that is a subsidiary, parent, or affiliate of a Holder that is a
corporation, or (d) a transferee or assignee who is a “family member” (defined for purposes of this Section 1.12 as a spouse, ancestor, lineal descendant or sibling) of such Holder or a trust, the sole beneficiaries of which are
the Holder and /or family members of such Holder (each, a “Permitted Transferee”), provided that the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such
Permitted Transferee and the securities with respect to which such registration rights are being assigned; and provided, further, that such assignment shall be effective only if the Permitted Transferee agrees in writing to be bound by
the obligations of a Holder under this Agreement, including without limitation the provisions of Section 1.14 below. All shares beneficially owned by affiliated entities or persons shall be aggregated together for purposes of determining
whether a transferee or assignee is a Permitted Transferee. As a condition of such aggregation, holders of a majority of the shares of the aggregating persons and entities shall designate in writing from time to time one representative for all
aggregating persons and entities, and the Company shall be entitled to definitively rely upon the authority of such representative and any action or omission of such representative in exercising or failing to exercise the rights hereunder.

 1.13 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not,
without the prior written consent of the Holders 

  

 -13- 

 
of (i) a majority of the outstanding Registrable Securities consisting of Common Stock issued or issuable upon the conversion of Series A Preferred
Stock, (ii) a majority of the outstanding Registrable Securities consisting of Common Stock issued or issuable upon the conversion of Series B Preferred Stock, (iii) ) a majority of the outstanding Registrable Securities consisting of
Common Stock issued or issuable upon the conversion of Series C Preferred Stock, (iv) a majority of the outstanding Registrable Securities consisting of Common Stock issued or issuable upon the conversion of Series D Preferred Stock
and (v) a majority of the outstanding Registrable Securities consisting of Common Stock issued or issuable upon the conversion of Series E Preferred Stock, enter into any agreement with any holder or prospective holder of any securities of
the Company which would allow such holder or prospective holder to include such securities in any registration filed under Section 1.2 or Section 1.4 hereof, unless under the terms of such agreement, such holder or prospective holder may
include such securities in any such registration only to the extent that the inclusion of his securities will not reduce the amount of the Registrable Securities of the Holders which is included. 
 1.14 Lock-Up Agreement.  
 (a)
Lock-Up Period; Agreement. In connection with the initial public offering of the Company’s securities and upon request of the Company or the underwriters managing such offering of the Company’s securities, each Holder agrees
not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company, however or whenever acquired (other than those included in the registration) without the prior written consent of
the Company or such underwriters, as the case may be, for such period of time (not to exceed 180 days) from the effective date of such registration as may be requested by the Company and such managing underwriters and to execute an agreement
reflecting the foregoing as may be requested by the underwriters at the time of the Company’s initial public offering. 
 (b)
Limitations. The obligations described in Section 1.14(a) shall apply only if all officers, directors, and greater than 1% stockholders (on an as converted and as exercised basis) of the Company enter into similar agreements, and
shall not apply to a registration relating solely to employee benefit plans, or to a registration relating solely to a transaction pursuant to Rule 145 under the Securities Act. Any discretionary waiver or termination of the restrictions contained
in such similar agreements by the Company or the underwriter shall apply to all Holders (according to the total amount of Registrable Securities owned by each Holder). 
 (c) Stop-Transfer Instructions. In order to enforce the foregoing covenants, the Company may impose stop-transfer instructions with respect to the securities of each Holder (and the securities of every
other person subject to the restrictions in Section 1.14(a)). 
 1.15 Termination of Registration Rights. No Holder shall
be entitled to exercise any right provided for in this Section 1 after the earlier of (i) five (5) years following the consummation of a Qualified IPO, or (ii) such time as Rule 144 or another similar exemption under the
Securities Act is available for the immediate sale of all of such Holder’s shares during a three-month period without registration. 
  

 -14- 

 2. Covenants of the Company. 
 2.1 Delivery of Financial Statements; Other Reports. The Company shall deliver any holder of Series B Preferred Stock, Series C Preferred
Stock, Series D Preferred Stock or Series E Preferred Stock or Common Stock issued upon conversion of such Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock and to each Holder of at least
500,000 shares of Registrable Securities (other than a Holder reasonably deemed by the Company to be a competitor of the Company): 
 (a) as
soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company (or such later date as the Board of Directors may approve), an income statement for such fiscal year, a balance sheet of the Company
and statement of stockholder’s equity as of the end of such year, and a statement of cash flows for such year, such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles
(“GAAP”), certified by the Company’s Chief Financial Officer (or equivalent) and audited and certified by an independent public accounting firm of nationally recognized standing selected by the Company; and 
 (b) within forty-five (45) days of the end of each fiscal quarter, an unaudited income statement and a statement of cash flows and balance sheet
for and as of the end of such quarter, in reasonable detail, and which shall be certified by the Chief Financial Officer (or equivalent); and 
 (c) within thirty (30) days of the end of each month, an unaudited income statement and a statement of cash flows and balance sheet for and as of the end of such month, in reasonable detail, and which shall be certified by the Chief
Financial Officer (or equivalent); and 
 (d) as soon as practicable, but in any event thirty (30) days prior to the end of each fiscal
year, a budget and business plan for the next fiscal year, prepared on a monthly basis, and, as soon as prepared, any other budgets or revised budgets prepared by the Company; and 
 (e) promptly after the submission thereof to the Company, copies of all final reports and recommendations submitted by independent public accountants in
connection with any annual or interim audit of the accounts of the Company made by such accountants; and 
 (f) with reasonable promptness,
such other financial data relating to the business, affairs and financial condition of the Company as is available to the Company and as from time to time the Purchasers may reasonably request. 
 2.2 Inspection. The Company shall permit any holder of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or
Series E Preferred Stock or 

  

 -15- 

 
Common Stock issued upon conversion of such Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock and
each Holder of at least 500,000 shares of Registrable Securities (except for a Holder reasonably deemed by the Company to be a competitor of the Company), and any of its partners, officers or employees, or any outside representatives designated by
such Holder and reasonably satisfactory to the Company, at such holder’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts
with its officers, lawyers and accountants, all at such reasonable times as may be requested by the Investor; provided, however, that the Company shall not be obligated pursuant to this Section 2.2 to provide access to any
information which it reasonably considers, upon the advice of legal counsel, to be a trade secret or similar confidential information unless the holder requesting the opportunity to examine such trade secret or similar confidential information
(x) is not, in the reasonable judgment of the Company, a competitor of the Company and (y) enters into a non-disclosure agreement with the Company reasonably acceptable to the Company and the holder regarding such trade secret or similar
confidential information. 
 2.3 Right of First Offer. Subject to the terms and conditions specified in this Section 2.3,
the Company hereby grants to each Major Investor (as hereinafter defined) a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). For purposes of this Section 2.3, a “Major
Investor” shall mean any person who holds at least 250,000 shares of the Series A Preferred Stock (or the Common Stock issued upon conversion thereof), at least 250,000 shares of Series B Preferred Stock (or Common Stock issued
upon conversion thereof), at least 250,000 shares of Series C Preferred Stock (or Common Stock issued upon conversion thereof), at least 250,000 shares of Series D Preferred Stock (or Common Stock issued upon conversion thereof) or at
least 250,000 shares of Series E Preferred Stock (or Common Stock issued upon conversion thereof) or any individual or entity acquiring at least 50,000 shares of Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock
from the holder of at least 250,000 shares of Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock (in each case, as adjusted for stock splits, stock dividends and the like). For purposes of this Section 2.3, Major
Investor includes any general partners and affiliates of a Major Investor. A Major Investor who chooses to exercise the right of first offer may designate as purchasers under such right itself, its partners or affiliates in such proportions as it
deems appropriate or any individual or entity acquiring at least 50,000 shares of Registrable Securities from a Major Investor. 
 Each time
the Company proposes to offer any shares of, or securities convertible into or exchangeable or exercisable for any shares of, any class of its capital stock (“Shares”), the Company shall first make an offering of such Shares to each
Major Investor in accordance with the following provisions: 
 (a) The Company shall deliver a notice by certified mail
(“Notice”) to the Major Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such
Shares. 
  

 -16- 

 (b) Within 20 calendar days after delivery of the Notice, the Major Investor may elect to purchase or
obtain, at the price and on the terms specified in the Notice, up to that portion of such Shares which equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible or
exercisable securities then held, by such Major Investor bears to the total number of shares of Common Stock then outstanding (assuming full conversion, exchange and exercise of all convertible, exchangeable or exercisable securities). Such purchase
shall be completed at the same closing as that of any third party purchasers or at an additional closing thereunder. 
 (c) The Company may,
during the 60-day period following the expiration of the period provided in subsection 2.3(b) hereof, offer the remaining unsubscribed portion of the Shares to any person or persons at a price not less than, and upon terms no more favorable to
the offeree than those specified in the Notice. If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within 60 days of the execution thereof, the right provided
hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Major Investors in accordance herewith. 
 (d) The right of first offer in this paragraph 2.3 shall not be applicable to (i) the issuance of securities in connection with stock splits or dividends; (ii) the issuance or sale of up to 8,936,475 shares of Common Stock
(or options therefor) to employees, consultants and directors, pursuant to stock option or stock purchase plans or agreements approved by the Board of Directors for the primary purpose of soliciting or retaining their services; (iii) the
issuance of securities to financial institutions or lessors in connection with commercial credit arrangements, equipment financings, commercial property lease transactions, or similar transactions, the terms of which have been approved by the Board
of Directors; (iv) the issuance of securities pursuant to the conversion or exercise of convertible or exercisable securities currently outstanding (including the Series C Preferred Stock, Series D Preferred Stock and Series E Preferred
Stock); (v) the issuance of securities in connection with a bona fide acquisition, merger or similar transaction, the terms of which have been approved by the Board of Directors; (vi) the issuance of common stock in a public offering
approved by the Board of Directors prior to or in connection with which all outstanding shares of Preferred Stock will be converted to Common Stock; (vii) the issuance of securities to an entity, as a component of any business relationship with
such entity also involving a material marketing, distribution, product development and/or technology licensing arrangement approved by the Board of Directors; or (viii) the issuance of securities with the affirmative vote or written consent of
at least a majority of the then outstanding shares of Series A Preferred Stock, voting as a separate class, at least a majority of the then outstanding shares of Series B Preferred Stock, voting as a separate class, at least a majority of the then
outstanding shares of Series C Preferred Stock, voting as a separate class, at least a majority of the then outstanding shares of Series D Preferred Stock, voting as a separate class, and at least two-thirds (2/3) of the then outstanding shares
of Series E Preferred Stock. In addition to the foregoing, the right of first offer in this paragraph 2.3 shall not be applicable with respect to any Major Investor and any subsequent securities issuance, if (i) at the time of such subsequent
securities issuance, the Major Investor or designated affiliate or partner thereof is not an “accredited investor,” as that term is then defined in Rule 501(a) under the Securities Act, and (ii) such subsequent securities issuance is
otherwise being offered only to accredited investors. 
  

 -17- 

 (e) The holders of Registrable Securities, as that term is defined in the Prior Rights Agreement, on
behalf of themselves and all holders of Registrable Securities pursuant to Section 3.4 of the Prior Rights Agreement, hereby waive any right of first offer, including the notice requirements related thereto, set forth in Section 2.3 of the
Prior Rights Agreement with respect to the issuance of Series E Preferred Stock. 
 2.4 Insurance. 
 (a) The Company will, and will cause each subsidiary to, obtain and maintain in force such property damage, public liability, business interruption,
worker’s compensation, indemnity bonds and other types of insurance as the Company’s executive officers, after consultation with an accredited insurance broker, shall determine to be necessary or appropriate to protect the Company from the
insurable hazards or risks associated with the conduct of the Company’s business. The Company’s executive officers shall periodically report to the Board of Directors on the status of such insurance coverage. 
 (b) The Company has purchased and maintains, and shall continue to maintain, a “key person” life insurance policy, payable to the Company, on
the life of the Chief Executive Officer of the Company, in the amount of $2 million, and shall not assign or change the beneficiary of such policy or borrow against such policy. 
 (c) Promptly following the closing under the Purchase Agreement, the Company shall obtain and maintain in force directors and officers insurance in an
amount of not less than $5 million. 
 2.5 Directors’ and Stockholders’ Meetings. The Company shall promptly
reimburse in full the directors elected solely by the holders of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock for all their reasonable out-of-pocket expenses
incurred in connection with the attending of meetings of the Board of Directors of the Company or any committee thereof. The Company shall maintain directors’ and officers’ insurance in such amounts and with such company(ies) as shall be
reasonably acceptable to the Investors. The Company agrees, as a general practice, to hold a meeting of its Board of Directors at least four times each year, and during each year to hold its annual meeting of stockholders (or written consent in lieu
thereof) on or approximately on the date provided in its Bylaws. 
 2.6 Employee Nondisclosure and Noncompetition Agreements.
The Company shall obtain customary invention assignment, nondisclosure and nonsolicitation agreements from all employees and consultants, and will diligently enforce all of its rights under such agreements. 
 2.7 Independent Accountants. The Company will retain independent public accountants of recognized national standing approved by the
Company’s Board of Directors who 

  

 -18- 

 
shall audit the Company’s consolidated financial statements at the end of each fiscal year. In the event the services of the independent public
accountants, so selected, or any firm of independent public accountants hereafter employed by the Company are terminated, the Company will promptly thereafter engage another such firm of independent public accountants of national standing.

 2.8 Preservation Of Corporate Existence. The Company will preserve and maintain its corporate existence, rights, franchises
and privileges in the jurisdiction of its incorporation, and qualify and remain qualified, as a foreign corporation in each jurisdiction in which such qualification is necessary or desirable in view of its business and operations or the ownership of
its properties. 
 2.9 Compliance With Laws. The Company will use its best efforts to comply with all applicable laws, rules,
regulations and orders of any governmental authority, noncompliance with which could reasonably be expected to materially and adversely affect its business or condition, financial or otherwise. 
 2.10 Prompt Payment Of Taxes, Etc. The Company will promptly pay and discharge, or cause to be paid and discharged, when due and payable,
all material lawful taxes, assessments and governmental charges or levies imposed upon the income, profits, property or business of the Company; provided, however, that any such tax, assessment, charge or levy need not be paid if the
validity thereof shall currently be contested in good faith by appropriate proceedings and if the Company shall have set aside on its books adequate reserves with respect thereto, and provided, further, that the Company will pay all such taxes,
assessments, charges or levies forthwith upon the commencement of proceedings to foreclose any lien which may have attached as security therefor. The Company will promptly pay or cause to be paid when due, or in conformance with customary trade
terms, all other indebtedness incident to operations of the Company. 
 2.11 Maintenance Of Properties And Leases. The Company
will keep its properties in good repair, working order and condition, reasonable wear and tear excepted, and from time to time make all needful and proper repairs, renewals, replacements, additions and improvements thereto; and the Company will at
all times comply with each provision of all leases to which any of them is a party or under which any of them occupies property if the breach of such provision could reasonably be expected to have a material adverse effect on the condition,
financial or otherwise, or operations of the Company. 
 2.12 Independent Appraisal. Within three (3) months of the date
of this Agreement, the Company shall present to the Board of Directors an independent appraisal of the value of the Company’s Common Stock that meets the requirements of Section 401(a)(28)(C) of the Internal Revenue Code and the
regulations thereunder. 
 2.13 Termination of Covenants. 
 (a) The covenants set forth in Sections 2.1 through Section 2.12 shall terminate as to each Holder and be of no further force or effect
(i) immediately prior to the 

  

 -19- 

 
consummation of a Qualified IPO, or (ii) when the Company shall sell, convey, or otherwise dispose of all or substantially all of its property or
business or merge with or into or consolidate with any other corporation (other than a wholly-owned subsidiary corporation) or effect any other transaction or series of related transactions in which more than 50% of the voting power of the Company
is disposed of and the Company is not the survivor, provided that such covenants shall not be terminated following a merger effected solely for the purpose of changing the domicile of the Company. 
 (b) The covenants set forth in Sections 2.1 and 2.2 shall terminate as to each Holder and be of no further force or effect when the Company first
becomes subject to the periodic reporting requirements of Sections 13 or 15(d) of the Exchange Act, if this occurs earlier than the events described in this Section 2.13(a) above. 
 3. Miscellaneous. 
 3.1
Termination. Except for the obligations set forth in Section 1.10 herein, this Agreement shall terminate, and have no further force and effect five years following the consummation of a Qualified IPO. 
 3.2 Mergers, Etc. The Company shall not, directly or indirectly, enter into any merger, consolidation, or reorganization in which the
Company shall not be the surviving corporation unless the proposed surviving corporation shall, prior to such merger, consolidation, or reorganization, agree in writing to assume the obligations of the Company under this Agreement, and for that
purpose references hereunder to “Registrable Securities” shall be deemed to be references to the securities which the Holders would be entitled to receive in exchange for Registrable Securities under any such merger, consolidation, or
reorganization; provided, however, that the provisions of this Agreement shall not apply in the event of any merger, consolidation, or reorganization in which the Company is not the surviving corporation if the Holders of Registrable Securities are
entitled to receive in exchange therefor (i) cash or (ii) securities of the acquiring corporation that may be immediately sold without restriction to the public without registration under the Securities Act. 
 3.3 Successors and Assigns. Except as otherwise provided in this Agreement, the terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the respective permitted successors and assigns of the parties (including transferees of any of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E
Preferred Stock or any Common Stock issued upon conversion thereof). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 3.4 Amendments and
Waivers. Any term of this Agreement may be amended or waived only with the written consent of the Company and the holders of (i) a majority of the Registrable Securities then outstanding consisting of Common Stock issued or issuable
upon the conversion of Series A Preferred Stock, (ii) a majority of Registrable Securities 

  

 -20- 

 
then outstanding consisting of Common Stock issued or issuable upon the conversion of Series B Preferred Stock, (iii) a majority of Registrable
Securities then outstanding consisting of Common Stock issued or issuable upon the conversion of Series C Preferred Stock, (iv) a majority of Registrable Securities then outstanding consisting of Common Stock issued or issuable upon the
conversion of Series D Preferred Stock and (v) at least two-thirds (2/3) of Registrable Securities then outstanding consisting of Common Stock issued or issuable upon the conversion of Series E Preferred Stock. Notwithstanding the
foregoing, this Agreement may be amended with only the written consent of the Company for the sole purpose of including additional purchasers of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock
or Series E Preferred Stock as “Investors” and “Holders.” Any amendment or waiver effected in accordance with this paragraph shall be binding upon each party to the Agreement, whether or not such party has signed such amendment
or waiver, each future holder of all such Registrable Securities, and the Company. 
 3.5 Notices. Unless otherwise provided,
any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient upon delivery, when delivered personally or by overnight courier or sent by telegram or fax, or forty-eight (48) hours after being deposited
in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party to be notified at such party’s address or fax number as set forth on Exhibit A hereto or as subsequently modified by written notice, and,
if to the Company, with a copy to Heller Ehrman LLP, 275 Middlefield Road, Menlo Park, CA 94025, Fax: (650) 324-0638, Attn: Edward Y. Kim, and if to Caduceus Private Investments II, LP, Caduceus Private Investments II (QP), LP or UBS Juniper
Crossover Fund, L.L.C., 500 Fifth Avenue, New York, NY 10110, Fax: (212) 382-0050, Attn.: Mason H. Drake, and, if to Cargill Ventures, with a copy to Latham & Watkins LLP, Attn: Mark V. Roeder, 140 Scott Drive, Menlo Park, CA 94025,
Fax: 650-463-2600. 
 3.6 Severability. If one or more provisions of this Agreement are held to be unenforceable under
applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be excluded from this
Agreement, (b) the balance of the Agreement shall be interpreted as if such provision were so excluded and (c) the balance of the Agreement shall be enforceable in accordance with its terms. 
 3.7 Governing Law. This Agreement and all acts and transactions pursuant hereto shall be governed, construed and interpreted in accordance
with the laws of the State of California, without giving effect to principles of conflicts of laws. 
 3.8 Counterparts. This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 3.9 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
  

 -21- 

 3.10 Aggregation of Stock. All shares of the Preferred Stock held or acquired by affiliated
entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 [Signature Pages Follow] 
  

 -22- 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	COMPANY:                                     
                                        
                               
	
	EMPHASYS MEDICAL, INC.
	
	 By:   /s/ John G.
McCutcheon                                

	 John G. McCutcheon, President and Chief
Executive Officer

	
	 Address: 700 Chesapeake Drive

	                Redwood City, CA 94063

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

			
	INVESTORS:                                     
                                      
 
	
	CADUCEUS PRIVATE INVESTMENTS II, LP
	
	 By:    OrbiMed Capital II, LLC

	 its general partner

		
		  	By:    /s/ Jonathan Silverstein            
		  	Name:    Jonathan Silverstein            
		  	Title:   General
Partner                      
	
	CADUCEUS PRIVATE INVESTMENTS II (QP), LP
	
	 By:    OrbiMed Capital II, LLC

	 its general partner

		
		  	By:    /s/ Jonathan Silverstein            
		  	Name:    Jonathan Silverstein            
		  	Title:   General
Partner                      
	
	UBS JUNIPER CROSSOVER FUND, L.L.C.
	
	 By:    OrbiMed Advisors Inc.

	 as authorized signatory

		
		  	By:    /s/ Jonathan Silverstein            
		  	Name:    Jonathan Silverstein            
		  	Title:   General
Partner                      

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	MORGAN STANLEY DEAN WITTER VENTURE PARTNERS IV, L.P.
	MORGAN STANLEY DEAN WITTER VENTURE INVESTORS IV, L.P.
	MORGAN STANLEY DEAN WITTER VENTURE OFFSHORE INVESTORS IV, L.P.
	
	 By:   MSDW Venture Partners IV, L.L.C. as General Partner of each of the limited partnerships named above

	
	 By:   MSDW Venture Partners IV, Inc.

	
	By:    /s/ Melissa
Daniels                                       
 
	Name:    Melissa
Daniels                                       
 
	Title:    Vice
President                                       
     
	
	MORGAN STANLEY VENTURE PARTNERS 2002 FUND, L.P.
	MORGAN STANLEY VENTURE INVESTORS 2002 FUND, L.P.
	
	 By:   MSVP 2002 Fund, L.L.C. as General Partner of each of the limited partnerships named above

	
	 By:   MSVP 2002, Inc. as Member

	
	By:    /s/ Melissa
Daniels                                       
 
	Name:    Melissa
Daniels                                       
 
	Title:    Vice
President                                       
     

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	ST. PAUL VENTURE CAPITAL VI, LLC
	 By:    SPVC Management VI, LLC

	 Its:    Managing Member

	
	 By:    /s/ David W.
Stassen                    

	 Name:    David W.
Stassen                    

	 Title:    Managing
Director                    

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	 ADVANCED TECHNOLOGY VENTURES VI, L.P.
 By: ATV Associates VI, L.L.C., its General Partner

	
	By:     /s/ Michael A.
Carusi                                       
 
	            Michael A. Carusi, Managing
Director                            
	
	 ATV ENTREPRENEURS VI, L.P.
 By: ATV Associates VI,
L.L.C., its General Partner

	
	By:     /s/ Michael A.
Carusi                                       
 
	            Michael A. Carusi, Managing Director
	
	 ATV ALLIANCE 2001, L.P.
 By: ATV Alliance
Associates, L.L.C., its General Partner

	
	By:     /s/ Michael A.
Carusi                                       
 
	Name:     Michael A.
Carusi                                       
 
	Title:
    Director                                  
                        

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	 MORGENTHALER PARTNERS VII, L.P.
  
 By: Morgenthaler Management Partners VII, LLC
        Its General Partner

	
	By:             /s/ Gary
Shaffer                                       
 
	                        Member

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	 New Enterprise Associates VIII, Limited Partnership
  
 By: NEA Partners VIII, Limited Partnership
        its General Partner
 By: General Partner

	
	By:     /s/ C. Richard
Kramlich                                       
 
	Name:     C. Richard
Kramlich                                       
 
	Title:     General
Partner                                       
           
	
	 New Enterprise Associates 8A, Limited Partnership
 By: NEA Partners 10, Limited Partnership
        its General Partner
 By: General Partner

	
	By:     /s/ C. Richard
Kramlich                                       
 
	Name:     C. Richard
Kramlich                                       
 
	Title:     General
Partner                                       
           

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	 VLG INVESTMENTS 2006 LLC
 By: Heller Ehrman
LLP, manager

	
	By:     /s/ Mark
Royer                                        

	Name:     Mark
Royer                                        

	Title:     Fund
Manager                                       
 
	
	HEWM/VLG INVESTMENTS, LLC
	
	By:     /s/ Mark
Royer                                        

	Name:     Mark
Royer                                        

	Title:     Fund
Manager                                       
 
	
	 VLG ASSOCIATES 2000
 a California general
partnership

	
	By:     /s/ Mark
Royer                                        

	Name:     Mark
Royer                                        

	Title:     Fund
Manager                                       
 

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  
  
  

	
	INVESTORS:
	
	/s/ Mark B.
Weeks                                        

	Mark B. Weeks

  
  
  
  

	
	
	/s/ Edward Y.
Kim                                        

	Edward Y. Kim

  
  
  
 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  
  
  

	
	INVESTORS:
	
	ABS INVESTORS L.L.C.
	
	By:     /s/ Bruns H.
Grayson                                       
 
	Name:   Bruns H.
Grayson                                       
     
	Title:     Senior
Manager                                       
         

  
  

	
	ABS VENTURES VII L.P.
	
	By: Calvert Capital Caymans I L.L.C.
	
	By:     /s/ Bruns H.
Grayson                                       
 
	Name:   Bruns H.
Grayson                                       
     
	Title:     Senior
Manager                                       
         

  
  
  
 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	/s/ John G.
McCutcheon                                       
 
	John G. McCutcheon

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	        /s/ Anthony P.C.
Yim                                        

	Anthony P.C. Yim, MA, DM, FRCS, FACS, FCCP

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	        /s/ Kim
Kniest                                       
 
	Kim Kniest

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	TRELLIS HEALTH VENTURES II L.P.
	
	By:         /s/ Paul J.
Felton                                       
     
	Name:     Paul J.
Felton                                       
         
	Title:   Manager, THV Management II LLC                

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	Mendelson Family Trust
	
	By:         /s/ Alan C.
Mendelson                                  
	 Name:      Alan C. Mendelson

	 Title:         Trustee

	
	76 De Bell Drive
	Atherton, California 94027
	Phone: (650) 328-4600
	Fax: (650) 463-2600
	
	VP Company Investments 2004, LLC
	
	By:         /s/ Alan C.
Mendelson                                  
	 Name:      Alan C. Mendelson

	 Title:         Managing Member

	
	c/o Chief Financial Officer
	Latham & Watkins LLP
	555 West Fifth Street, Suite 800
	Los Angeles, CA 90013-1010
	Phone: (213) 891-7220
	Fax: (213) 891-7123
	
	        /s/ Mark V.
Roeder                                       
       
	Mark V. Roeder
	
	Attn: Mark V. Roeder
	Latham & Watkins LLP
	140 Scott Drive
	Menlo Park, California 94025
	Phone: (650) 328-4600
	Fax: (650) 463-2600

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

	
	INVESTORS:
	
	CARGILL, INCORPORATED
	
	By:         /s/ Sanjiv
Arora                                       
       
	Name:   Sanjiv
Arora                                       
             
	Title:     Vice President, Cargill
Ventures                  

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

 EXHIBIT A 
 INVESTORS 
 SERIES A INVESTORS 
  

			
	 Investor
	  	Number of Shares of Series A
Preferred Stock
	 ABS Investors L.L.C. 
 Susan Adams
 ABS Ventures
 890 Winter Street, Suite 225
 Waltham, MA 02451
 E-MAIL: susan.adams@absventures.com
	  	38,500
		
	 ABS Ventures VII L.P. 
 Susan Adams
 ABS Ventures
 890 Winter Street, Suite 225
 Waltham, MA 02451
 E-MAIL: susan.adams@absventures.com
	  	2,161,500
		
	 The Will Family Trust dated 10-3-88,
 Allan R. Will and Heidi E. Will, Trustees 
 c/o St. Paul Venture Capital
 1600 El Camino Real, Suite 290
 Menlo Park, CA 94025
	  	500,000
		
	 Henry A. Plain, Jr. 
 c/o The Foundry, LLC
 199 Jefferson Drive
 Menlo Park, CA 94025
	  	500,000
		
	 Frederick G. St. Goar 
	  	25,000
		
	 Soroush Kaboli 
	  	25,000
		
	 Philip John Webb & Evana Bronwyn Webb 
	  	50,000
		
	 The Beals Family Trust dated 7-28-97,
 Alyn T. Beals, Trustee 
 c/o Beals Martin Associates
 2596 Bay Road
 Redwood City, CA 94063
	  	25,000

			
	 Investor
	  	Number of Shares of Series A
Preferred Stock
	 John Hall
	  	10,000
		
	 VLG Investments LLC 
 c/o Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
 TEL: (650) 854-4488
 FAX: (650) 233-8386
	  	43,350
		
	 VLG Associates 2000 
 c/o Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
 TEL: (650) 854-4488
 FAX: (650) 233-8386
	  	6,650
		
	 Mark B. Weeks 
 c/o Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
 TEL: (650) 854-4488
 FAX: (650) 233-8386
	  	15,000
		
	 Mark Windfeld-Hansen 
 c/o Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
 TEL: (650) 854-4488
 FAX: (650) 233-8386
	  	10,000
		
	 Edward Y. Kim 
 c/o Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
 TEL: (650) 854-4488
 FAX: (650) 233-8386
	  	5,000
		
	 John G. McCutcheon and Stacey Paris McCutcheon,
 Trustees of the McCutcheon Family Trust UTD 7/19/99 
	  	500,000
		
	 The Fields/Ozer Family Trust 
	  	40,000
		
	 Total
	  	3,955,000

  

 SERIES B INVESTORS 
  

			
	 Investor
	  	 Number of Shares of Series B
 Preferred Stock

	 Advanced Technology Ventures VI, L.P. 
 485 Ramona Street
 Palo Alto, CA 94301
 TEL: 650-321-8601
 FAX: 650-321-0934
	  	2,217,222
		
	 ATV Entrepreneurs VI, L.P. 
 485 Ramona Street
 Palo Alto, CA 94301
 TEL: 650-321-8601
 FAX: 650-321-0934
	  	110,861
		
	 ATV Alliance 2001, L.P.
 485 Ramona Street
 Palo Alto, CA 94301
 TEL: 650-321-8601
 FAX: 650-321-0934
	  	5,250
		
	 Morgenthaler Partners VII, L.P.
 2730 Sand Hill Road, Suite 280
 Menlo Park, CA 94025
 TEL: 650-388-7600
 FAX: 650-388-7601
	  	2,333,333
		
	 ABS Investors L.L.C. 
 Susan Adams
 ABS Ventures
 890 Winter Street, Suite 225
 Waltham, MA 02451
 E-MAIL: susan.adams@absventures.com
	  	10,560
		
	 ABS Ventures VII L.P.
 Susan Adams
 ABS Ventures
 890 Winter Street, Suite 225
 Waltham, MA 02451
 E-MAIL: susan.adams@absventures.com
	  	989,440
		
	 Randy Campbell
	  	30,000
		
	 Rich Ferrick
 c/o Emphasys Medical
 700 Chesapeake Drive
 Redwood City, CA 94063
 TEL: (650) 364-0400
	  	20,000
		
	 Mary McCutcheon
	  	13,333

			
	 Investor
	  	 Number of Shares of Series B
 Preferred Stock

	 Jon Salveson
 Piper Jaffray
 800 Niccollet Avenue
 Minneapolis, MN 55402
 TEL: (612) 303-6363
	  	20,000
		
	 Tom Schnettler
 Piper Jaffray
 801 Niccollet Avenue
 Minneapolis, MN 55402
 TEL: (612) 303-6464
	  	20,000
		
	 Archie Smith
 Piper Jaffray
 802 Niccollet Avenue
 Minneapolis, MN 55402
 TEL: (612) 303-6263
	  	20,000
		
	 VLG Investments LLC
 275 Middlefield Road
 Menlo Park, CA 94025
 TEL: (650) 324-7000
 FAX: (650) 324-0638
	  	20,000
		
	 RGIP, LLC
 One International Place
 Boston, MA 02110-2624
 TEL: 617-951-7000
 FAX: 617-951-7050
	  	16,667
		
	 New Enterprise Associates VIII, Limited
 Partnership
 2490 Sand Hill Road
 Menlo Park, CA 94025
 TEL: (650) 854-9499
 FAX: (650) 854-9397
	  	52,800
		
	 New Enterprise Associates 8A, Limited
 Partnership
 2490 Sand Hill Road
 Menlo Park, CA 94025
 TEL: (650) 854-9499
 FAX: (650) 854-9397
	  	52,800
		
	 Getz Bros. Co. Ltd.
 150 Post Street, Suite 500
 San Francisco, CA 94108
 TEL: (415) 772-5500
 FAX: (415) 772-5659
	  	363,636
		
	 TOTAL:
	  	6,295,902

 SERIES C INVESTORS 
  

			
	 Investor
	  	 Number of Shares of Series C
 Preferred Stock

	 St. Paul Venture Capital VI, LLC
 10400 Viking Drive, Suite 550
 Eden Prairie, MN 55344
	  	3,333,333
		
	 Advanced Technology Ventures VI, L.P.
 485 Ramona Street
 Palo Alto, CA 94301-1708
	  	3,174,603
		
	 ATV Entrepreneurs VI, L.P.
 485 Ramona Street
 Palo Alto, CA 94301-1708
	  	158,730
		
	 Morgenthaler Partners VII, L.P.
 2710 Sand Hill Road, Suite 100
 Menlo Park, CA 94025
	  	2,000,000
		
	 ABS Ventures HC, L.P.
 Susan Adams
 ABS Ventures
 890 Winter Street, Suite 225
 Waltham, MA 02451
 E-MAIL: susan.adams@absventures.com
	  	1,000,000
		
	 New Enterprise Associates VIII, Limited Partnership
 1119 St. Paul Street
 Baltimore, MD 21202
	  	100,000
		
	 New Enterprise Associates 8A, Limited Partnership
 1119 St. Paul Street
 Baltimore, MD 21202
	  	100,000
		
	 Scott Grant
	  	100,000
		
	 Sandra Wanner
	  	16,666
		
	 Paula Doran
	  	30,000
		
	 Scott Hesler
	  	16,666
		
	 Mike Padgett
	  	16,666
		
	 TOTAL:
	  	10,046,664

 SERIES D INVESTORS 
  

			
	 Name of Investor
	  	 Number of Shares of Series D
 Preferred Stock

	 Caduceus Private Investments II, LP
 c/o OrbiMed Advisors, LLC
 767 Third Avenue, 30th Floor
 New York, NY 10017-2023
	  	3,843,602
		
	 Caduceus Private Investments II (QP), LP
 c/o OrbiMed Advisors, LLC
 767 Third Avenue, 30th Floor
 New York, NY 10017-2023
	  	1,439,124
		
	 UBS Juniper Crossover Fund, L.L.C.
 c/o OrbiMed Advisors, LLC
 767 Third Avenue, 30th Floor
 New York, NY 10017-2023
	  	476,436
		
	 Morgan Stanley Dean Witter Venture Partners IV, L.P.
 c/o Morgan Stanley Venture Partners
 3000 Sand Hill Road
 Building 4, Suite 250
 Menlo Park, CA 94025
 Attn: Melissa Daniels
	  	1,359,861
		
	 Morgan Stanley Dean Witter Venture Investors IV, L.P.
 c/o Morgan Stanley Venture Partners
 3000 Sand Hill Road
 Building 4, Suite 250
 Menlo Park, CA 94025
 Attn: Melissa Daniels
	  	157,766
		
	 Morgan Stanley Dean Witter Venture Offshore Investors IV, L.P.
 c/o Morgan Stanley Venture Partners
 3000 Sand Hill Road
 Building 4, Suite 250
 Menlo Park, CA 94025
 Attn: Melissa Daniels
	  	53,054
		
	 Morgan Stanley Venture Partners 2002 Fund, L.P.
 c/o Morgan Stanley Venture Partners
 3000 Sand Hill Road
 Building 4, Suite 250
 Menlo Park, CA 94025
 Attn: Melissa Daniels
	  	1,208,497

			
	 Name of Investor
	  	 Number of Shares of Series D
 Preferred Stock

	 Morgan Stanley Venture Investors 2002 Fund, L.P.
 c/o Morgan Stanley Venture Partners
 3000 Sand Hill Road
 Building 4, Suite 250
 Menlo Park, CA 94025
 Attn: Melissa Daniels
	  	362,183
		
	 St. Paul Venture Capital VI, LLC
 10400 Viking Drive
 Eden Prairie, MN 55344
	  	1,570,680
		
	 Advanced Technology Ventures VI, L.P.
 485 Ramona Street
 Palo Alto, CA 94301-1708
	  	1,844,927
		
	 ATV Entrepreneurs VI, L.P.
 485 Ramona Street
 Palo Alto, CA 94301-1708
	  	92,246
		
	 Morgenthaler Partners VII, L.P.
 2710 Sand Hill Road, Suite 100
 Menlo Park, CA 94025
	  	1,570,680
		
	 New Enterprise Associates 8A, Limited Partnership
 1119 St. Paul Street
 Baltimore, MD 21202
 Attn: Pamela Clark
	  	259,162
		
	 Scott Grant
	  	100,000
		
	 Bruce W. Schwab
 Townsend and Townsend and Crew LLP
 Two Embarcadero Center
 Eighth Floor
 San Francisco, CA 94111-3834
 (415) 576-0200
 bwschwab@townsend.com
	  	18,325
		
	 Todd Cornell
	  	10,000
		
	 HEWM/VLG Investments, LLC
 Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
	  	20,942

			
	 Name of Investor
	  	 Number of Shares of Series D
 Preferred Stock

	 Mark B. Weeks
 c/o Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
	  	2,617
		
	 Edward Y. Kim
 c/o Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
	  	5,235
		
	 TOTAL:
	  	14,395,337
		  	 

 SERIES E INVESTORS 
  

			
	 Investor
	  	Number of Shares of Series E
Preferred Stock
	 Cargill, Incorporated
 1200 Park Place, Suite 300
 San Mateo, CA 94403
	  	22,916,667
		
	 Caduceus Private Investments II, LP
 c/o OrbiMed Advisors, LLC
 767 Third Avenue, 30th Floor
 New York, NY 10017-2023
	  	556,157
		
	 Caduceus Private Investments II (QP), LP
 c/o OrbiMed Advisors, LLC
 767 Third Avenue, 30th Floor
 New York, NY 10017-2023
	  	208,237
		
	 UBS Juniper Crossover Fund, L.L.C.
 c/o OrbiMed Advisors, LLC
 767 Third Avenue, 30th Floor
 New York, NY 10017-2023
	  	68,939
		
	 Morgan Stanley Dean Witter Venture Partners IV, L.P.
 c/o Morgan Stanley Venture Partners
 3000 Sand Hill Road
 Building 4, Suite 250
 Menlo Park, CA 94025
 Attn: Melissa Daniels
	  	174,554
		
	 Morgan Stanley Dean Witter Venture Investors IV, L.P.
 c/o Morgan Stanley Venture Partners
 3000 Sand Hill Road
 Building 4, Suite 250
 Menlo Park, CA 94025
 Attn: Melissa Daniels
	  	20,251
		
	 Morgan Stanley Dean Witter Venture Offshore Investors IV, L.P.
 c/o Morgan Stanley Venture Partners
 3000 Sand Hill Road
 Building 4, Suite 250
 Menlo Park, CA 94025
 Attn: Melissa Daniels
	  	6,810

			
	 Investor
	  	Number of Shares of Series E
Preferred Stock
	 Morgan Stanley Venture Partners 2002 Fund, L.P.
 c/o Morgan Stanley Venture Partners
 3000 Sand Hill Road
 Building 4, Suite 250
 Menlo Park, CA 94025
 Attn: Melissa Daniels
	  	155,125
		
	 Morgan Stanley Venture Investors 2002 Fund, L.P.
 c/o Morgan Stanley Venture Partners
 3000 Sand Hill Road
 Building 4, Suite 250
 Menlo Park, CA 94025
 Attn: Melissa Daniels
	  	46,490
		
	 St. Paul Venture Capital VI, LLC
 10400 Viking Drive
 Eden Prairie, MN 55344
 Attn: Lisa Corbin
	  	629,487
		
	 Advanced Technology Ventures VI, L.P.
 485 Ramona Street
 Palo Alto, CA 94301-1708
 Attn: Elaine Caughey
	  	929,563
		
	 ATV Entrepreneurs VI, L.P.
 485 Ramona Street
 Palo Alto, CA 94301-1708
 Attn: Elaine Caughey
	  	46,478
		
	 Morgenthaler Partners VII, L.P.
 2710 Sand Hill Road, Suite 100
 Menlo Park, CA 94025
 Attn: G. Gary Shaffer
	  	757,848
		
	 New Enterprise Associates VIII, Limited Partnership
 1119 St. Paul Street
 Baltimore, MD 21202
 Attn: Pamela Clark
	  	62,500
		
	 New Enterprise Associates 8A, Limited Partnership
 1119 St. Paul Street
 Baltimore, MD 21202
 Attn: Pamela Clark
	  	62,500
		
	 ABS Ventures VII L.P.
 ABS Ventures
 890 Winter Street, Suite 225
 Waltham, MA 02451
 Attn: Susan Adams
	  	629,650

			
	 Investor
	  	Number of Shares of Series E
Preferred Stock
	 Anthony P.C. Yim, MA, DM, FRCS, FACS, FCCP
 Professor of Surgery and Chief of Cardiothoracic Surgery
 The Chinese University of Hong Kong
 Prince of Wales Hospital
 Shatin, N.T.
 Hong Kong
 Tel: (852) 2632 2629
 Fax: (852) 2647 8273
 e-mail:yimap@cuhk.edu.hk
	  	33,333
		
	 VLG Investments 2006 LLC
 c/o Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
 Attn: Mark Royer
	  	22,916
		
	 Mark B. Weeks
 c/o Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
	  	4,166
		
	 Edward Y. Kim
 c/o Heller Ehrman LLP
 275 Middlefield Road
 Menlo Park, CA 94025
	  	4,166
		
	 Trellis Health Ventures II L.P.
 425 Market Street, Ste 2200
 San Francisco, CA 94105
 415 951 4799
 Attn: Paul J. Felton
	  	208,333
		
	 Kim Kniest
	  	5,208
		
	 Mendelson Family Trust
	  	3,800

  

			
	 Investor
	  	Number of Shares of Series E
Preferred Stock
	 VP Company Investments 2004, LLC
 c/o Chief Financial Officer
 Latham & Watkins LLP
 555 West Fifth Street, Suite 800
 Los Angeles, CA 90013-1010
 Phone: (213) 891-7220
 Fax: (213) 891-7123
	  	5,300
		
	 Mark V. Roeder
 Latham & Watkins LLP
 140 Scott Drive
 Menlo Park, California 94025
 Phone: (650) 328-4600
 Fax: (650) 463-2600
	  	1,500
		
	 TOTAL:
	  	7,559,978Amendment to Fourth Amended and Restated Investors' Rights Agreement

 EXHIBIT 4.3 
 EMPHASYS MEDICAL, INC. 
 AMENDMENT TO 
 FOURTH AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT 

This Amendment (the “Amendment”) to the Fourth Amended and Restated Investors’ Rights Agreement dated June 29, 2006 (the
“Agreement”), is made as of this 5th day of September 2007 by and among Emphasys Medical, Inc., a Delaware corporation (the “Company”), the undersigned holders of Registrable Securities (as such term is defined
therein) (the “Purchasers”) and each of Venture Lending & Leasing IV, LLC (“VLL IV”) and Venture Lending & Leasing V, LLC (“VLL V”). 
 RECITALS 
 A. The Company and each of
Venture Lending & Leasing IV, Inc. and Venture Lending and Leasing V, Inc. (which are wholly owned by VLL IV and VLL V, respectively) have entered into that certain Loan and Security Agreement of even date herewith (the “Loan
Agreement”), pursuant to which the Company has issued to each of VLL IV and VLL V a warrant to purchase shares of Preferred Stock (the “Warrant Shares”). 
 B. The parties desire to amend the Agreement to provide that the New Purchaser will be deemed to be an “Investor” and a “Holder” with
respect to certain rights and obligations under the Agreement, and to make such other changes set forth below. 
 D. The parties hereto
desire to enter into this Amendment in accordance with Section 3.4 of the Agreement. 
 IT IS THEREFORE AGREED THAT: 
 1. Definitions. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Agreement. 
 2. Amendments. 
 (a) Section 1.1
is hereby amended to add the following subsection: 
 “(h) The term “VLL Warrants” means the warrants issued to each of
Venture Lending & Leasing IV, LLC (“VLL IV”) and Venture Lending & Leasing V, LLC (“VLL V”) on September 5, 2007, for the purchase of Preferred Stock.” 
 (b) Section 1.1(b) is hereby amended to read in its entirety as follows: 
 “(b) The term “Registrable Securities” means (i) the shares of Common Stock issuable or issued upon conversion of the Series A
Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, 

 
Series D Preferred Stock or Series E Preferred Stock other than shares for which registration rights have terminated pursuant to Section 1.15 hereof,
(ii) the shares of Common Stock issuable upon conversion of the Preferred Stock issuable or issued upon exercise of the VLL Warrants (as defined below) (provided, however, that for the purposes of Section 1.2, the Holders of
the VLL Warrants may not be Initiating Holders), and (iii) any other shares of Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of, the shares listed in (i) and (ii); provided, however, that the foregoing definition shall exclude in all cases any Registrable Securities sold by a person in a transaction
in which his or her rights under this Agreement are not assigned. Notwithstanding the foregoing, Common Stock or other securities shall only be treated as Registrable Securities if and so long as they have not been (A) sold to or through a
broker or dealer or underwriter in a public distribution or a public securities transaction, (B) sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof, in
each case so that all transfer restrictions, and restrictive legends with respect thereto, if any, are removed upon the consummation of such sale, or (C) the Holder thereof is entitled to exercise any right provided in Section 1 in
accordance with Section 1.15 hereof;” 
 (c) Section 1.1(g) is hereby amended to read in its entirety as follows: 

“(g) The term “Qualified IPO” means a firm commitment underwritten public offering by the Company of shares of its Common Stock
pursuant to a registration statement under the Securities Act, which results in aggregate cash proceeds to the Company of $30,000,000 (net of underwriting discounts and commissions).” 
 Notwithstanding the foregoing, in the event that the Company does not complete a Qualified IPO on or before March 31, 2008, the foregoing amendment in this
Section 2(c) shall be null and void, and the language set forth in Section 1.1(g) of the Agreement prior to the date of this Amendment shall remain in full force and effect 
 (d) Each of VLL IV and VLL V hereby agrees to be bound by all of the terms and conditions of the Agreement applicable to Investors and Holders.

 3. Effect of Amendment. The undersigned Investors hold the requisite majority of the currently outstanding Registrable Securities
to approve the foregoing amendment, in accordance with Section 3.4 of the Agreement. Except as amended as set forth above, the Agreement shall continue in full force and effect. 
  

 2 

 4. Counterparts. This Amendment may be signed in one or more counterparts, each of which shall be
deemed an original and all of which, taken together, shall be deemed one and the same document. 
  

 3 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.

  

			
	COMPANY:
	  
  
 EMPHASYS MEDICAL, INC.

		
	By:	 	 /s/ John G. McCutcheon        

			
		
	Name: 	 	John G. McCutcheon

			
		
	Title: 	 	President and Chief Executive Officer

 SIGNATURE PAGE TO AMENDMENT TO 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.

  

			
	VLL IV AND VLL V:
	  
 VENTURE LENDING & LEASING IV, LLC
  

	By:	 	 /s/ Maurice C. Werdegar        

			
		
	Name: 	 	 Maurice C. Werdegar

			
		
	Title: 	 	 Vice President

  
  

			
	 VENTURE LENDING & LEASING V, LLC
  

	By:	 	 /s/ Maurice C. Werdegar        

			
		
	Name: 	 	 Maurice C. Werdegar

			
		
	Title: 	 	 Vice President

 SIGNATURE PAGE TO AMENDMENT TO 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

			
	INVESTORS:
	
	 ADVANCED TECHNOLOGY VENTURES VI, L.P.
 By: ATV Associates VI, L.L.C., its General Partner

		
	By:	 	    /s/ Michael A. Carusi
		 	    Managing Director
	
	 ATV ENTREPRENEURS VI, L.P.
 By: ATV
Associates VI, L.L.C., its General Partner

		
	By:	 	    /s/ Michael A. Carusi
		 	    Managing Director
	
	 ATV ALLIANCE 2001, L.P.
 By:
ATV Alliance Associates, L.L.C., its General Partner

		
	By:	 	    /s/ Michael A. Carusi
		 	    Director

 SIGNATURE PAGE TO AMENDMENT TO 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

			
	INVESTORS:
	
	 MORGENTHALER PARTNERS VII, L.P.
  
 By: Morgenthaler Management Partners VII, LLC
        Its General Partner

		
	By:	 	    /s/ Theodore Laufik
		 	     Chief Financial Officer & Managing
     Member

	
	 SPVC VI, LLC
 By: SPVC
Management VI, LLC
 Its: Managing Member

		
	By:	 	    /s/ Allan R. Will
		
	Title:	 	 
	
	CARGILL, INCORPORATED
		
	By:	 	    /s/ Sanjiv Arora
		
	Title:	 	    Vice President

 SIGNATURE PAGE TO AMENDMENT TO 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

			
	INVESTORS:
	
	ABS INVESTORS L.L.C.
		
	By:	 	    /s/ R.C. Spalding
		 	    R.C. Spalding, Manager
	
	 ABS VENTURES HC, L.P.
  
 By: Calvert Capital III L.L.C., its general partner

		
	By:	 	    /s/ R.C. Spalding
		 	    R.C. Spalding, Manager

 SIGNATURE PAGE TO AMENDMENT TO 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

			
	 MORGAN STANLEY DEAN WITTER VENTURE
 PARTNERS IV, L.P.
 MORGAN STANLEY DEAN WITTER VENTURE
 INVESTORS IV, L.P.
 MORGAN STANLEY DEAN WITTER VENTURE
 OFFSHORE INVESTORS IV, L.P
  
 By: MSDW Venture Partners IV, L.L.C. as General Partner
        of each of the limited
partnerships named above
  
 By: MSDW Venture Partners IV, Inc.

		
	By:	 	    /s/ Melissa Daniels
		
	Title:	 	    Executive Director
	
	 MORGAN STANLEY VENTURE PARTNERS
 2002 FUND, L.P.
 MORGAN STANLEY VENTURE INVESTORS
 2002 FUND, L.P.
  
 By: MSVP 2002 Fund, L.L.C. as General Partner of each

        of the limited partnerships named above
  
 By: MSVP 2002, Inc. as Member

		
	By:	 	    /s/ Melissa Daniels
		
	Title:	 	    Executive Director

 SIGNATURE PAGE TO AMENDMENT TO 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

			
	 CADUCEUS PRIVATE INVESTMENTS II, LP
 CADUCEUS PRIVATE INVESTMENTS II (QP), LP
  
         By: OrbiMed Capital II, LLC
         its General Partner

		
	By:	 	    /s/ Jonathan Silverstein
		
	Title:	 	    General Partner
	
	 UBS JUNIPER CROSSOVER FUND, L.L.C.
  
         By: OrbiMed Advisors Inc.
         as authorized signatory

		
	By:	 	    /s/ Jonathan Silverstein
		
	Title:	 	    General Partner

 SIGNATURE PAGE TO AMENDMENT TO 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]